Skip directly to search
Skip directly to A to Z list
Skip directly to navigation
Skip directly to page options
Skip directly to site content
Start of Search Controls
Search Form Controls
Search The CDC
submit
CDC A-Z Index
MENU
CDC A-Z
SEARCH
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Search Form Controls
Search The CDC
submit
CDC A-Z Index
Public Health Genomics and Precision Health Knowledge Base (v9.0)
PHGKB
About
Public Health Genomics Branch
PHGKB Weekly Horizon Scan
Genomics Precision Health Scan
Advanced Molecular Detection Clips
Non-Genomics Precision Health Scan
CDC-authored Publications Scan
Specialized PHGKB
Cancer PHGKB
Diabetes PHGKB
Economic Evaluation PHGKB
Environmental Health PHGKB
Family Health History PHGKB
Health Equity PHGKB
HLBS-PopOmics
Infectious Diseases PHGKB
Implementation Science PHGKB
Neurological Disorders PHGKB
Pharmacogenomics PHGKB
Primary Immune Deficiency Diseases PHGKB
Rare Diseases PHGKB
Reproductive and Child Health PHGKB
All Databases
COVID-19 GPH (47370)
CDC/NIH Web Information Database (32181)
CDC-Authored Genomics and Precision Health Publications Database (5878)
Precision Health Database (63675)
Tier-Classified Guidelines Database (534)
Pathogen Advanced Molecular Detection Database (26775)
All of Us Reports and Publications Database (676)
Human Genome Epidemiology
Human Genome Epidemiology Literature Finder (226516)
Epigenetic Epidemiology Publications Database (22780)
Release Note
Contact Us
Precision Health Database
Precision Health Database|Search|Public Health Genomics and Precision Health Knowledge Base (PHGKB)
Rare Diseases
Last data update: Apr 25, 2024
. (Total: 63675 Documents since 2012)
All
Cancer
Diabetes
Economic
Equity
Environmental
FHH
HLBS
ID
Implementation
ND
PGx
PI
Rare
RCH
dataset
All
GPH
Non-GPH
Filtered By
:
Select to fine-tune your search
Disease
Gene
Product Type
Category
Year
Previous
Records 1 - 30 (of 35 Records)
Next
Query Trace:
Pharmacogenetics to prevent hypersensitivity reactions to antiepileptic drugs: is testing performed when indicated?
Vy L Bui et al. Pharmacogenet Genomics 2023
Similar articles in PubMed
Cost-effectiveness of HLA-B*58:01 testing to prevent Stevens-Johnson syndrome/toxic epidermal necrolysis in Vietnam.
Khanh Nc Duong et al. Pharmacogenomics 2023
Similar articles in PubMed
Updates on the immunopathology and genomics of severe cutaneous adverse drug reactions.
Andrew Gibson et al. The Journal of allergy and clinical immunology 2023 151(2) 289-300.e4
Similar articles in PubMed
A Comprehensive Review of HLA and Severe Cutaneous Adverse Drug Reactions: Implication for Clinical Pharmacogenomics and Precision Medicine.
Kloypan Chiraphat et al. Pharmaceuticals (Basel, Switzerland) 2021 14(11)
Similar articles in PubMed
Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art.
Jantararoungtong Thawinee et al. Expert opinion on drug metabolism & toxicology 2021
Similar articles in PubMed
A Novel Real-Time PCR Assay for Detection of HLA-A*31:01 in Individuals Being Considered for Carbamazepine Therapy.
Krause David S et al. CNS spectrums 2021 26(2) 154-155
Similar articles in PubMed
Implementation of Pharmacogenomic Information on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Tsukagoshi Eri et al. Frontiers in medicine 2021 8644154
Similar articles in PubMed
Cost-effectiveness analysis of genotyping for HLA-B*15:02 in Indonesian patients with epilepsy using a generic model.
Yuliwulandari Rika et al. The pharmacogenomics journal 2021
Similar articles in PubMed
Mapping of susceptible variants for cold medicine-related Stevens–Johnson syndrome by whole-genome resequencing
Y Kawai et al, NPJ Genomic Medicine, February 2021
Genetic Markers for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in the Asian Indian Population: Implications on Prevention.
Shanbhag Swapna S et al. Frontiers in genetics 2020 11607532
Similar articles in PubMed
Real-time clinical note monitoring to detect conditions for rapid follow-up: A case study of clinical trial enrollment in drug-induced torsades de pointes and Stevens-Johnson syndrome.
DeLozier Sarah et al. Journal of the American Medical Informatics Association : JAMIA 2020 Oct
Similar articles in PubMed
Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions.
Chang Chih-Jung et al. Frontiers in pharmacology 2020 11969
Similar articles in PubMed
Genetic Variants Associated with T-Cell Mediated Cutaneous Adverse Drug Reactions: A Prisma-Compliant Systematic Review - an EAACI Position Paper.
Oussalah Abderrahim et al. Allergy 2020 Jan
Similar articles in PubMed
Association of carbamazepine-induced Stevens–Johnson syndrome/toxic epidermal necrolysis with the HLA-B75 serotype or HLA-B*15:21 allele in Filipino patients
F Capule et al, PGX journal. January 3, 2020
Genetic Predisposition to Anticonvulsant Hypersensitivity
M Pirmohamed, CPT, September 2019
Genetic testing for prevention of severe drug-induced skin rash.
Alfirevic Ana et al. The Cochrane database of systematic reviews 2019 Jul 7CD010891
Similar articles in PubMed
Cost-effectiveness of screening for HLA-B*1502 prior to initiation of carbamazepine in epilepsy patients of Asian ancestry in the United States.
Choi Hyunmi et al. Epilepsia 2019 Jun
Similar articles in PubMed
Stevens-Johnson syndrome/toxic epidermal necrolysis in Jewish and Arab populations.
Firer Maria et al. Epilepsia 2018 59(7) 1469-1470
Similar articles in PubMed
Pharmacogenomic Advances in the Prediction and Prevention of Cutaneous Idiosyncratic Drug Reactions.
Pan R-Y et al. Clinical pharmacology and therapeutics 2017 102(1) 86-97
Similar articles in PubMed
Incidental Pharmacogenetics Findings in an HLA-related Research: Considerations for Primary Prevention.
Bakhtiar Faizal et al. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2019 Jan
Similar articles in PubMed
Pharmacogenomics- Choosing the right medication at the right dose for each patient
NHGRI, Apr 2018
Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese Population.
Mushiroda Taisei et al. JAMA neurology 2018 Apr
Similar articles in PubMed
The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
Jutkowitz Eric et al. Seminars in arthritis and rheumatism 2017 Apr 46(5) 594-600
Similar articles in PubMed
Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update.
Phillips Elizabeth J et al. Clinical pharmacology and therapeutics 2018 Feb
Similar articles in PubMed
Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
Chong Huey Yi et al. Pharmacogenetics and genomics 2017 Nov
Similar articles in PubMed
Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.
Manolio Teri A et al. Clinical pharmacology and therapeutics 2017 Nov
Similar articles in PubMed
Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment.
Chen Zhibin et al. Neurology 2016 Mar 86(12) 1086-94
Similar articles in PubMed
Personalized medicine approaches in epilepsy.
Walker L E et al. J. Intern. Med. 2015 Feb (2) 218-34
Similar articles in PubMed
When a Genetic ID Card is the Difference Between Life and Death,
By Ed Yong, the Atlantic, October 5, 2015
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
Similar articles in PubMed
File Formats Help:
How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?
Adobe PDF file
Microsoft PowerPoint file
Microsoft Word file
Microsoft Excel file
Audio/Video file
Apple Quicktime file
RealPlayer file
Text file
Zip Archive file
SAS file
ePub file
Page last reviewed:
Feb 1, 2024
Page last updated:
Apr 25, 2024
Content source:
Public Health Genomics Branch in the Division of Blood Disorders and Public Health Genomics
,
National Center on Birth Defects and Developmental Disabilities
TOP